BRPI0811947A2 - COMPOUND, PROCESS FOR PREPARATION OF A COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND OBESITY TREATMENT METHOD, TYPE II DIABETES, DYSLIPIDEMIA OR METABOLIC SYNDROME - Google Patents
COMPOUND, PROCESS FOR PREPARATION OF A COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND OBESITY TREATMENT METHOD, TYPE II DIABETES, DYSLIPIDEMIA OR METABOLIC SYNDROMEInfo
- Publication number
- BRPI0811947A2 BRPI0811947A2 BRPI0811947-3A2A BRPI0811947A BRPI0811947A2 BR PI0811947 A2 BRPI0811947 A2 BR PI0811947A2 BR PI0811947 A BRPI0811947 A BR PI0811947A BR PI0811947 A2 BRPI0811947 A2 BR PI0811947A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- dyslipidemia
- diabetes
- preparation
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93130307P | 2007-05-22 | 2007-05-22 | |
| US93127307P | 2007-05-22 | 2007-05-22 | |
| US93132707P | 2007-05-22 | 2007-05-22 | |
| US93136907P | 2007-05-22 | 2007-05-22 | |
| PCT/EP2008/055843 WO2008141976A1 (en) | 2007-05-22 | 2008-05-13 | Diacylglycerol acyltransferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0811947A2 true BRPI0811947A2 (en) | 2014-11-11 |
Family
ID=39619031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0811947-3A2A BRPI0811947A2 (en) | 2007-05-22 | 2008-05-13 | COMPOUND, PROCESS FOR PREPARATION OF A COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND OBESITY TREATMENT METHOD, TYPE II DIABETES, DYSLIPIDEMIA OR METABOLIC SYNDROME |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2155687A1 (en) |
| CN (1) | CN101835757B (en) |
| AU (1) | AU2008253118B2 (en) |
| BR (1) | BRPI0811947A2 (en) |
| CA (1) | CA2686951C (en) |
| HK (1) | HK1148519A1 (en) |
| MX (1) | MX2009012285A (en) |
| WO (1) | WO2008141976A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1833806A1 (en) | 2004-12-14 | 2007-09-19 | AstraZeneca AB | Oxadiazole derivatives as dgat inhibitors |
| US7749997B2 (en) | 2005-12-22 | 2010-07-06 | Astrazeneca Ab | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors |
| CA2647819C (en) | 2006-03-31 | 2012-12-11 | Novartis Ag | Phenylcyclohexyl derivatives as dgat1 inhibitors |
| US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
| US8153644B2 (en) | 2007-05-22 | 2012-04-10 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| US8058299B2 (en) | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| US8115011B2 (en) | 2007-05-22 | 2012-02-14 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| WO2008148851A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
| AU2008258549B2 (en) | 2007-06-08 | 2013-11-14 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine/Piperazine derivatives |
| CA2687754C (en) | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
| AR066169A1 (en) | 2007-09-28 | 2009-07-29 | Novartis Ag | DERIVATIVES OF BENZO-IMIDAZOLES, USEFUL FOR DISORDERS ASSOCIATED WITH THE ACTIVITY OF DGAT |
| WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
| US8211884B2 (en) | 2008-08-06 | 2012-07-03 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| AU2009316786A1 (en) | 2008-11-19 | 2010-05-27 | Merck Sharp & Dohme Corp. | Inhibitors of diacylglycerol acyltransferase |
| CA2744152A1 (en) * | 2008-12-03 | 2010-06-10 | Via Pharmaceuticals, Inc. | Inhibitors of diacylglycerol acyltransferase |
| CA2745445A1 (en) * | 2008-12-17 | 2010-07-08 | Via Pharmaceuticals, Inc. | Inhibitors of diacylglycerol aclytransferase |
| JP5642661B2 (en) * | 2009-03-05 | 2014-12-17 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having NPYY5 receptor antagonistic activity |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| WO2011078102A1 (en) * | 2009-12-22 | 2011-06-30 | 第一三共株式会社 | Novel phenoxypyrimidine derivative |
| WO2012050159A1 (en) | 2010-10-14 | 2012-04-19 | 田辺三菱製薬株式会社 | Amide derivative and use thereof |
| WO2012063896A1 (en) * | 2010-11-11 | 2012-05-18 | 第一三共株式会社 | Novel pyrazole amide derivative |
| US9453003B2 (en) * | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| US9458151B2 (en) * | 2011-08-11 | 2016-10-04 | Jikai Biosciences, Inc. | Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| US9452995B2 (en) * | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| CN102924446B (en) * | 2011-08-11 | 2015-08-26 | 上海吉铠医药科技有限公司 | PIM kinase inhibitor and preparation method thereof and the application in pharmacy |
| EP2837627B1 (en) | 2012-04-13 | 2017-01-18 | Mitsubishi Tanabe Pharma Corporation | Amidopyridine derivative, and use thereof |
| CN104557765A (en) * | 2015-02-10 | 2015-04-29 | 佛山市赛维斯医药科技有限公司 | Halophenyl thiazolecarboxylic acid amide double-target inhibitor containing amidine structure, as well as preparation method and application thereof |
| CN104672164A (en) * | 2015-02-10 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | SGLT2/SGLT1 double-target inhibitor containing benzene amidine structure as well as preparation method and application of inhibitor |
| CN104710382A (en) * | 2015-02-10 | 2015-06-17 | 佛山市赛维斯医药科技有限公司 | Halogeneated phenyl thiazole carboxylic acid amides compounds containing tertiary butyl amidine structures and application |
| CN104610187B (en) * | 2015-02-10 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | One class is containing alkoxyphenyl radical thiazole carboxylic acid amides class two target spot inhibitor, the Preparation Method And The Use of amidine structure |
| CN104610189A (en) * | 2015-02-10 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | SGLT2/SGLT1 double-target-point inhibitor containing cyclopropyl amidine structure and application of SGLT2/SGLT1 double-target-point inhibitor |
| CN104672165B (en) * | 2015-02-10 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | One class is containing alkoxyphenyl radical thiazole carboxylic acid amides's class two target spot inhibitor, the Preparation Method And The Use of cyclopropyl amidine structure |
| CN104592151A (en) * | 2015-02-10 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Tert-butyl amidine structure containing SGLT2/SGLT1 dual-target inhibitor and application thereof |
| CN104672166A (en) * | 2015-02-10 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | Cyanophenyl thiazolecarboxylic acid amide double-target inhibitor containing amidine structure as well as preparation method and application of inhibitor |
| CN104592149A (en) * | 2015-02-10 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Tert-butyl amidine structure containing alkoxyphenyl thiazolecarboxylic acid amide dual-target inhibitor, as well as preparation method and application thereof |
| MY195528A (en) | 2016-03-17 | 2023-01-30 | Hoffmann La Roche | 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar |
| CN111148743B (en) | 2017-10-06 | 2023-12-15 | 福马治疗有限公司 | Inhibition of ubiquitin-specific peptidase 30 |
| CA3110113A1 (en) | 2018-10-05 | 2020-04-09 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04001850A (en) * | 2001-08-31 | 2004-06-15 | Aventis Pharma Gmbh | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators. |
| US7553867B2 (en) * | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| JP2008543747A (en) * | 2005-06-11 | 2008-12-04 | アストラゼネカ アクチボラグ | Oxadiazole derivatives as DGAT inhibitors |
| KR20080063865A (en) * | 2005-11-28 | 2008-07-07 | 에프. 호프만-라 로슈 아게 | Inhibitors of diacylglycerol acyltransferase (dgat) |
-
2008
- 2008-05-13 MX MX2009012285A patent/MX2009012285A/en active IP Right Grant
- 2008-05-13 AU AU2008253118A patent/AU2008253118B2/en not_active Ceased
- 2008-05-13 WO PCT/EP2008/055843 patent/WO2008141976A1/en active Application Filing
- 2008-05-13 CA CA2686951A patent/CA2686951C/en not_active Expired - Fee Related
- 2008-05-13 CN CN200880025656.1A patent/CN101835757B/en not_active Expired - Fee Related
- 2008-05-13 EP EP08759547A patent/EP2155687A1/en not_active Withdrawn
- 2008-05-13 BR BRPI0811947-3A2A patent/BRPI0811947A2/en not_active IP Right Cessation
-
2011
- 2011-03-15 HK HK11102583.6A patent/HK1148519A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2686951A1 (en) | 2008-11-27 |
| CA2686951C (en) | 2016-03-22 |
| CN101835757A (en) | 2010-09-15 |
| AU2008253118B2 (en) | 2013-11-21 |
| HK1148519A1 (en) | 2011-09-09 |
| CN101835757B (en) | 2014-03-05 |
| EP2155687A1 (en) | 2010-02-24 |
| WO2008141976A1 (en) | 2008-11-27 |
| AU2008253118A1 (en) | 2008-11-27 |
| MX2009012285A (en) | 2009-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0811947A2 (en) | COMPOUND, PROCESS FOR PREPARATION OF A COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND OBESITY TREATMENT METHOD, TYPE II DIABETES, DYSLIPIDEMIA OR METABOLIC SYNDROME | |
| BRPI0818244A2 (en) | Compound, pharmaceutical composition, use of a compound, and method for treating a disorder or disease | |
| BRPI0814825A2 (en) | COMPOUND, PROCESS FOR THE PREPARATION OF COMPOUND, PHARMACEUTICAL COMPOSITION UNDERSTANDING ITS USE AND METHODS FOR TREATMENT OR PROPHYLAXY OF DIABETES, OBESITY, DISORDERS OF FOOD OR DISLIPIMEDIA AND TYPE II DIABETES | |
| BRPI0913585A2 (en) | compound, method for making a compound, pharmaceutical composition, use of a compound, and method for treating or preventing disorders | |
| BRPI0917458A2 (en) | compound, method of treating disease and conditions, pharmaceutical composition, method for treating or preventing disease, and use of a compound | |
| BRPI0715531A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATMENT OF A NURSING AND / OR METABOLIC DISORDER, PROCESS FOR PREPARATION OF COMPOUNDS AND USE OF COMPOUND | |
| BRPI0717657A2 (en) | COMPOUNDS, PROCESS FOR THE PREPARATION OF A COMPOUND, PHARMACEUTICAL COMPOSITION UNDERSTANDING, USES OF COMPOUNDS, METHODS FOR DIABETES TREATMENT AND PROPHYLAXY, OBESITY, DIETARY DISORDER AND DIPHYPETHYDIA DYPYTHESIA | |
| BRPI0907977A2 (en) | Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease | |
| BRPI0813237A2 (en) | COMPOUND, METHOD FOR PREPARING COMPOUND, COMPOSITION, MEDICINE, AND, USE OF COMPOUND. | |
| BRPI0818533A2 (en) | compound, pharmaceutical composition, and process for the preparation of a compound | |
| BRPI0812851A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OF A DISEASE AND CONDITION IN AN INDIVIDUAL, PROCESS FOR PREPARING A COMPOUND, AND USE OF A COMPOUND | |
| BRPI0816881A2 (en) | Compound, pharmaceutical composition, use of a compound, and methods for treating diseases or disorders and for preparing a compound. | |
| BRPI0914927A2 (en) | compound, pharmaceutical composition, methods for inhibiting fak function and cancer treatment, use of a compound, and process for preparing a compound | |
| BRPI0907974A2 (en) | Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease | |
| BR122020011920A2 (en) | compound, pharmaceutical composition, method of treating a disease, use of a compound, and processes for preparing a compound, and for manufacturing a compound | |
| BRPI0819799A2 (en) | Compound, intermediate, use of a compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease | |
| BRPI0922475A2 (en) | compound, pharmaceutical composition, method for treating cancer, and use of a compound. | |
| BRPI0810246A2 (en) | Dpp-iv inhibitors including the beta-amino group, method of preparation thereof and pharmaceutical composition containing the same for the prevention and treatment of diabetes or obesity. | |
| BRPI0924669A2 (en) | compound, use of a compound, method for treating diabetes mellitus and / or obesity, and pharmaceutical composition | |
| BR112012029227A2 (en) | process for the preparation of a chiral compound, chiral compound, composition, pharmaceutical composition, use of a composition, method of treatment or prevention and use of a compound | |
| BRPI0915084A2 (en) | compound, process for preparing a compound, pharmaceutical composition, use of a compound, methods for the prophylaxis or treatment of a disease state or condition and cancer | |
| BRPI0911685A2 (en) | compound, method for treating a disease, use of a compound, pharmaceutical composition, and kit | |
| BRPI0815493A2 (en) | COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PAIN THERAPY METHOD, AND PROCESS FOR PREPARING A COMPOUND. | |
| BRPI0815591A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREATING A DISEASE, CONDITION OR DISTURBANCE. | |
| BRPI0908883A2 (en) | compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |